Press Announcements > FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss

Press Announcements > FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss

	The U.S. Food and Drug Administration today approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult patients with an inherited form of vision loss that may result in blindness. Luxturna is the first directly administered gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene. Continue reading.